What are some of the new therapies discussed at ASH 2024?
A roundtable discussion on anemia management in
patient
Diagnosis of TP53-mutated myeloid disease by the ICC and WHO fifth edition classifications
Key Points
The ICC and WHO5 differently classify 64% of TP53-mutated disease due to distinct criteria for multihit TP53 mutations and TP53-mutated AML.
ACROBAT interim results support AlloHeme for relapse prediction in AML, MDS
Genome sequencing in the management of myelodysplastic syndromes and related disorders
Abstract
Oppose 57% Cut to Congressionally Directed Medical Research Programs
Oppose 57% Cut to Congressionally Directed Medical Research Programs
Take Action Before House Vote
Oppose 57% Cut to Congressionally Directed Medical Research Programs
Tell your Members of Congress to Vote NO on The Full-Year Continuing Appropriations and Extensions Act, 2025
Make Your Voice Count!
Join us in endorsing the recent appeal to Congress with the following actions. Your voice is important to continue these services for patients and provide opportunities for researchers to find the cures.
Letter on the Bipartisan Senate FY25 Labor-HHS-Education Appropriations Bill
AAMDSIF is Taking a Stand for NIH Research
Aplastic Anemia and Transplant
Pediatric Nurse Finds her Way through Aplastic Anemia Treatment
Pediatric nurse to medical student to patient? This was Claire's life. Listen to her story here.
State of the Art Treatment in Myelodysplastic Syndromes
Presenter: Mikkael SekeresProfessor of Medicine, Chief, Division of Hematology, Sylvester Comprehensive Cancer Center, University of Miami Miller School of MedicineMiami, FL, USA
Release Date: December 20, 2024
Congress: ASH 2024
Area: Hematology